Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TUDCA + Camrelizumab + Regorafenib in Advanced HCC
NCT07100392Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tauroursodeoxycholic acid in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Aug 2025; status: recruiting.
02
Drugs
tauroursodeoxycholic acid
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07100392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100392.